Sunday , 20 January 2019
Breaking News

Tag Archives: zydus

Zydus Wellness gets approval to raise Rs 1,500 crore via NCDs

Zydus Wellness has received approval to raise funds of aggregate nominal value up to Rs 1,500 crore through issuance of rated, secured, listed, redeemable, Non-Convertible Debentures (NCDs) each having a face value of Rs 10 lakh on private placement basis. The Board of Directors of the Company at its meeting held on January 11, 2019 has approved the same. Zydus ... Read More »

Zydus receives approval from USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel

Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate and Benzoyl Peroxide Gel, (US RLD-DUAC Gel), 1.2%/5%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris). It helps to decrease the number of acne pimples. Clindamycin is ... Read More »

Cadila Healthcare enters into agreement with Zydus Wellness

Cadila Healthcare has entered into a share subscription agreement (SSA) with Zydus Wellness (ZWL), a subsidiary Company, to subscribe to 85,02,170 equity shares at an issue price of Rs 1,382 amounting to Rs 1174.99 crore. Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth ... Read More »

Zydus Wellness enters into separate share subscription agreements

Zydus Wellness has entered into separate share subscription agreements (SSAs) with True North Fund V LLP and True North Fund VI LLP, Pioneer Investment Fund, Cadila Healthcare and Zydus Family Trust, for subscribing to the equity shares of the company, proposed to be issued on a preferential basis. Zydus Wellness is an integrated consumer company. The company is engaged in ... Read More »

Zydus Wellness planning to raise funds on private placement basis

Zydus Wellness is planning to raise funds through issue of securities on a preferential allotment basis and raising debt through issue of secured or unsecured redeemable, Non-Convertible Debentures (NCDs) on private placement basis. The Board of Directors of the Company at its meeting to be held on December 06, 2018, to consider the same. Zydus Wellness is an integrated consumer ... Read More »

Zydus Cadila receives tentative approval from USFDA for Deferasirox Tablets

Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Deferasirox Tablets, 90 mg, 180 mg, and 360 mg (US RLD – Exjade Tablets). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad in the state of Gujarat. It is used to treat ongoing high levels of iron ... Read More »

Zydus Cadila receives USFDA’s approval for Abacavir & Lamivudine Tablets, Fondaparinux Sodium Injection

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Abacavir and Lamivudine Tablets USP, 600 mg/300 mg (US RLD- EPZICOM), and Fondaparinux Sodium Injection USP, 2.5 mg/0.5 mL, 5 mg/0.4 mL 7.5 mg/0.6 mL and 10 mg/0.8 mL single-dose (US RLD- ARIXTRA). Abacavir and Lamivudine Tablets are used with other antiretroviral ... Read More »

Zydus Cadila gets USFDA’s approval for Nystatin and Triamcinolone Acetonide Ointment

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD -Mycolog-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug ... Read More »

Zydus Cadila gets final approval from USFDA for Clobazam Tablets

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Clobazam Tablets, (US RLD-ONFI Tablet), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Clobazam is used in combination with other medications to treat seizures caused by a paediatric epilepsy syndrome (termed as Lennox-Gastaut ... Read More »

Zydus Cadila receives approval from USFDA for Colchicine Tablets

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Colchicine Tablets USP (US RLD – ColcyrsTM), 0.6 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to prevent or treat attacks of gout (also called gouty arthritis). This condition is caused by high uric ... Read More »

Zydus Cadila gets final approval from USFDA for Clobetasol Propionate Cream

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Clobetasol Propionate Cream, (USRLD Temovate Cream), 0.05%. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Clobetasol Propionate is a topical (for the skin) steroid used to treat inflammation and itching caused by a number of skin conditions such ... Read More »